메뉴 건너뛰기




Volumn 5, Issue , 2012, Pages 221-229

Denosumab: A new option in the treatment of bone metastases from urological cancers

Author keywords

Bone metastasis; Denosumab; Prostate cancer; Renal cell cancer; Urothelial cancer; Zoledronic acid

Indexed keywords

CISPLATIN; CYSTEINE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; GEMCITABINE; METHOTREXATE; MINODRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PREDNISOLONE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TECHNETIUM 99M; THREONINE; VINBLASTINE; ZOLEDRONIC ACID;

EID: 84872176005     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S30578     Document Type: Review
Times cited : (16)

References (67)
  • 1
    • 4644261592 scopus 로고    scopus 로고
    • Mechanisms of bone metastasis
    • Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004; 350(16):1655-1664.
    • (2004) N Engl J Med , vol.350 , Issue.16 , pp. 1655-1664
    • Roodman, G.D.1
  • 3
    • 79961032286 scopus 로고    scopus 로고
    • Local treatment of metastatic cancer - killing the seed or disturbing the soil?
    • Morgan SC, Parker CC. Local treatment of metastatic cancer - killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011;8(8):504-506.
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.8 , pp. 504-506
    • Morgan, S.C.1    Parker, C.C.2
  • 5
    • 0037009822 scopus 로고    scopus 로고
    • Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
    • Saad F, Gleason DM, Murray R, T et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458-1468.
    • (2002) J Natl Cancer Inst , vol.94 , Issue.19 , pp. 1458-1468
    • Saad, F.1    Gleason, D.M.2    Murray, R.3
  • 6
    • 0042914647 scopus 로고    scopus 로고
    • Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
    • Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21(16):3150-3157.
    • (2003) J Clin Oncol , vol.21 , Issue.16 , pp. 3150-3157
    • Rosen, L.S.1    Gordon, D.2    Tchekmedyian, S.3
  • 7
    • 4644340347 scopus 로고    scopus 로고
    • Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid
    • Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res. 2004;10(18 Pt 2):6397S-6403S.
    • (2004) Clin Cancer Res , vol.10 , Issue.18 PART 2
    • Lipton, A.1    Colombo-Berra, A.2    Bukowski, R.M.3    Rosen, L.4    Zheng, M.5    Urbanowitz, G.6
  • 8
    • 20644449488 scopus 로고    scopus 로고
    • Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial
    • Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23(15):3314-3321.
    • (2005) J Clin Oncol , vol.23 , Issue.15 , pp. 3314-3321
    • Kohno, N.1    Aogi, K.2    Minami, H.3
  • 9
    • 4444257291 scopus 로고    scopus 로고
    • RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis
    • Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004;1704(2):49-57.
    • (2004) Biochim Biophys Acta , vol.1704 , Issue.2 , pp. 49-57
    • Wittrant, Y.1    Théoleyre, S.2    Chipoy, C.3
  • 10
    • 3242781731 scopus 로고    scopus 로고
    • Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases
    • Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA. 2004; 292(4):490-495.
    • (2004) JAMA , vol.292 , Issue.4 , pp. 490-495
    • Hofbauer, L.C.1    Schoppet, M.2
  • 11
    • 33644760436 scopus 로고    scopus 로고
    • A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer
    • Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res. 2006;12(4):1221-1228.
    • (2006) Clin Cancer Res , vol.12 , Issue.4 , pp. 1221-1228
    • Body, J.J.1    Facon, T.2    Coleman, R.E.3
  • 12
    • 79952761418 scopus 로고    scopus 로고
    • Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    • Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29(9):1125-1132.
    • (2011) J Clin Oncol , vol.29 , Issue.9 , pp. 1125-1132
    • Henry, D.H.1    Costa, L.2    Goldwasser, F.3
  • 13
    • 84873890067 scopus 로고    scopus 로고
    • Treatment of advanced renal cell carcinoma
    • In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
    • Srinivasan R, Linehan WM. Treatment of advanced renal cell carcinoma. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:1475-1491.
    • (2011) Campbell-Walsh Urology , pp. 1475-1491
    • Srinivasan, R.1    Linehan, W.M.2
  • 14
    • 34247390131 scopus 로고    scopus 로고
    • European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline
    • Ljungberg B, Hanbury DC, Kuczyk MA, et al; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 2007;51(6):1502-1510.
    • (2007) Eur Urol , vol.51 , Issue.6 , pp. 1502-1510
    • Ljungberg, B.1    Hanbury, D.C.2    Kuczyk, M.A.3
  • 15
    • 79955524407 scopus 로고    scopus 로고
    • Treatment outcome and prognostic factors of the patients with renal cell cancer bone metastasis
    • Yuasa T, Urakami S, Yamamoto S, et al. Treatment outcome and prognostic factors of the patients with renal cell cancer bone metastasis. Clin Exp Metastasis. 2011;28(4):405-411.
    • (2011) Clin Exp Metastasis , vol.28 , Issue.4 , pp. 405-411
    • Yuasa, T.1    Urakami, S.2    Yamamoto, S.3
  • 16
    • 79955522836 scopus 로고    scopus 로고
    • Management of Bone Metastasis in patients with Renal Cell Carcinoma and Other Malignancies of the Genitourinary Tract
    • In: Kantoff P, Saad F, Smith MR, editors, Philadelphia, PA: FA Davis Co
    • Lipton A. Management of Bone Metastasis in patients with Renal Cell Carcinoma and Other Malignancies of the Genitourinary Tract. In: Kantoff P, Saad F, Smith MR, editors. Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies. Philadelphia, PA: FA Davis Co; 2004:207-234.
    • (2004) Management of Skeletal Complications of Prostate Cancer and Other Genitourinary Malignancies , pp. 207-234
    • Lipton, A.1
  • 17
    • 0035433874 scopus 로고    scopus 로고
    • The skeletal metastatic complications of renal cell carcinoma
    • Zekri J, Ahmed N, Coleman RE, Hancock B W. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19(2): 379-382.
    • (2001) Int J Oncol , vol.19 , Issue.2 , pp. 379-382
    • Zekri, J.1    Ahmed, N.2    Coleman, R.E.3    Hancock, B.W.4
  • 18
    • 72149129759 scopus 로고    scopus 로고
    • Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: A cooperative group report of 1463 patients
    • Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010;57:317-325.
    • (2010) Eur Urol , vol.57 , pp. 317-325
    • Naito, S.1    Yamamoto, N.2    Takayama, T.3
  • 19
    • 25844458959 scopus 로고    scopus 로고
    • Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer
    • quiz i-ii
    • Kuczyk MA, Anastasiadis AG, Zimmermann R, Merseburger AS, Corvin S, Stenzi A. Current aspects of the surgical management of organ-confined, metastatic, and recurrent renal cell cancer. BJU Int. 2005;96(5):721-727; quiz i-ii.
    • (2005) BJU Int , vol.96 , Issue.5 , pp. 721-727
    • Kuczyk, M.A.1    Anastasiadis, A.G.2    Zimmermann, R.3    Merseburger, A.S.4    Corvin, S.5    Stenzi, A.6
  • 20
    • 34249102574 scopus 로고    scopus 로고
    • Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone
    • Toyoda Y, Shinohara N, Harabayashi T, et al. Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone. Eur Urol. 2007;52(1):163-168.
    • (2007) Eur Urol , vol.52 , Issue.1 , pp. 163-168
    • Toyoda, Y.1    Shinohara, N.2    Harabayashi, T.3
  • 21
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20(1):289-296.
    • (2002) J Clin Oncol , vol.20 , Issue.1 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3    Russo, P.4    Mazumdar, M.5
  • 23
    • 84866248292 scopus 로고    scopus 로고
    • Management of metastatic and invasive bladder cancer
    • Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
    • Lerner SP, Sternberg CN. Management of metastatic and invasive bladder cancer In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:2355-2374.
    • (2011) Campbell-Walsh Urology , pp. 2355-2374
    • Lerner, S.P.1    Sternberg, C.N.2
  • 25
    • 79955629384 scopus 로고    scopus 로고
    • European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines
    • Stenzl A, Cowan NC, De Santis M, et al; European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011;59(6):1009-1018.
    • (2011) Eur Urol , vol.59 , Issue.6 , pp. 1009-1018
    • Stenzl, A.1    Cowan, N.C.2    de Santis, M.3
  • 26
    • 0035495693 scopus 로고    scopus 로고
    • Locally advanced and metastatic bladder cancer
    • Dreicer R. Locally advanced and metastatic bladder cancer. Curr Treat Options Oncol. 2001;2(5):431-436.
    • (2001) Curr Treat Options Oncol , vol.2 , Issue.5 , pp. 431-436
    • Dreicer, R.1
  • 27
    • 0018956045 scopus 로고
    • Metastases from transitional cell carcinoma of urinary bladder
    • Babaian RJ, Johnson DE, Llamas L, Ayala AG. Metastases from transitional cell carcinoma of urinary bladder. Urology. 1980;16(2): 142-144.
    • (1980) Urology , vol.16 , Issue.2 , pp. 142-144
    • Babaian, R.J.1    Johnson, D.E.2    Llamas, L.3    Ayala, A.G.4
  • 28
    • 0042477610 scopus 로고    scopus 로고
    • The systemic treatment of advanced and metastatic bladder cancer
    • Hussain SA, James ND. The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol. 2003;4(8):489-497.
    • (2003) Lancet Oncol , vol.4 , Issue.8 , pp. 489-497
    • Hussain, S.A.1    James, N.D.2
  • 29
    • 0037103074 scopus 로고    scopus 로고
    • Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
    • Bellmunt J, Albanell J, Paz-Ares L, et al; Spanish Oncology Genitourinary Group. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer. 2002;95(4):751-757.
    • (2002) Cancer , vol.95 , Issue.4 , pp. 751-757
    • Bellmunt, J.1    Albanell, J.2    Paz-Ares, L.3
  • 30
    • 33646892392 scopus 로고    scopus 로고
    • I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
    • Tsukamoto T, Yonese J, Ohkubo Y, Fukui I. Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma. Cancer. 2006;106(11):2363-2368.
    • (2006) Cancer , vol.106 , Issue.11 , pp. 2363-2368
    • Tsukamoto, T.1    Yonese, J.2    Ohkubo, Y.3    Phase, F.I.4
  • 31
    • 56449100346 scopus 로고    scopus 로고
    • Hormonal therapy of prostate cancer
    • In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors, 10th ed. New York, NY: Saunders
    • Nelson JB. Hormonal therapy of prostate cancer. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ, editors. Campbell-Walsh Urology. 10th ed. New York, NY: Saunders; 2011:2934-2953.
    • (2011) Campbell-Walsh Urology , pp. 2934-2953
    • Nelson, J.B.1
  • 32
    • 2642548279 scopus 로고    scopus 로고
    • Natural history of early, localized prostate cancer
    • Johansson JE, Andrén O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291(22):2713-2719.
    • (2004) JAMA , vol.291 , Issue.22 , pp. 2713-2719
    • Johansson, J.E.1    Andrén, O.2    Andersson, S.O.3
  • 33
    • 41949104346 scopus 로고    scopus 로고
    • Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    • Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159.
    • (2008) J Clin Oncol , vol.26 , Issue.7 , pp. 1148-1159
    • Scher, H.I.1    Halabi, S.2    Tannock, I.3
  • 34
    • 4744337716 scopus 로고    scopus 로고
    • Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
    • Petrylak D P, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1513-1520
    • Petrylak, D.P.1    Tangen, C.M.2    Hussain, M.H.3
  • 35
    • 4744366279 scopus 로고    scopus 로고
    • TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    • Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
    • (2004) N Engl J Med , vol.351 , Issue.15 , pp. 1502-1512
    • Tannock, I.F.1    de Wit, R.2    Berry, W.R.3
  • 36
  • 37
    • 0842278680 scopus 로고    scopus 로고
    • Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anti- cancer drugs in leukemic cell lines
    • Kimura S, Kuroda J, Segawa H, et al. Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anti- cancer drugs in leukemic cell lines. Int J Hematol. 2004;79(1):37-43.
    • (2004) Int J Hematol , vol.79 , Issue.1 , pp. 37-43
    • Kimura, S.1    Kuroda, J.2    Segawa, H.3
  • 38
    • 10444274954 scopus 로고    scopus 로고
    • Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines
    • Matsumoto S, Kimura S, Segawa S, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer. 2005;47: 31-39.
    • (2005) Lung Cancer , vol.47 , pp. 31-39
    • Matsumoto, S.1    Kimura, S.2    Segawa, S.3
  • 39
    • 33646107396 scopus 로고    scopus 로고
    • Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro
    • Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006;27(2):92-103.
    • (2006) Tumour Biol , vol.27 , Issue.2 , pp. 92-103
    • Neville-Webbe, H.L.1    Evans, C.A.2    Coleman, R.E.3    Holen, I.4
  • 40
    • 0035917560 scopus 로고    scopus 로고
    • Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
    • Jagdev S P, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001;84(8): 1126-1134.
    • (2001) Br J Cancer , vol.84 , Issue.8 , pp. 1126-1134
    • Jagdev, S.P.1    Coleman, R.E.2    Shipman, C.M.3
  • 41
    • 5344237455 scopus 로고    scopus 로고
    • Osteoporosis and obesity in men receiving hormone therapy for prostate cancer
    • Smith MR. Osteoporosis and obesity in men receiving hormone therapy for prostate cancer. J Urol. 2004;172(5 Pt 2):S52-S56.
    • (2004) J Urol , vol.172 , Issue.5 PART 2
    • Smith, M.R.1
  • 42
    • 58249123472 scopus 로고    scopus 로고
    • Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy
    • Wang W, Yuasa T, Tsuchiya N, et al. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer. 2008;15(4):943-952.
    • (2008) Endocr Relat Cancer , vol.15 , Issue.4 , pp. 943-952
    • Wang, W.1    Yuasa, T.2    Tsuchiya, N.3
  • 43
    • 77951666249 scopus 로고    scopus 로고
    • Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients
    • Yuasa T, Maita S, Tsuchiya N, et al. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urolog y. 2010;75(5):1131-1137.
    • (2010) Urolog Y , vol.75 , Issue.5 , pp. 1131-1137
    • Yuasa, T.1    Maita, S.2    Tsuchiya, N.3
  • 44
    • 84928580276 scopus 로고
    • Hodges VC. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate
    • Huggins C, Hodges VC. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
    • (1941) Cancer Res , vol.1 , pp. 293-297
    • Huggins, C.1
  • 45
    • 0042463650 scopus 로고    scopus 로고
    • National practice patterns and time trends in androgen ablation for localized prostate cancer
    • Cooperberg MR, Grossfeld GD, Lubeck D P, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst. 2003;95(13):981-989.
    • (2003) J Natl Cancer Inst , vol.95 , Issue.13 , pp. 981-989
    • Cooperberg, M.R.1    Grossfeld, G.D.2    Lubeck, D.P.3    Carroll, P.R.4
  • 46
    • 22144484150 scopus 로고    scopus 로고
    • Androgen deprivation therapy for prostate cancer
    • Sharif N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244.
    • (2005) JAMA , vol.294 , Issue.2 , pp. 238-244
    • Sharif, N.1    Gulley, J.L.2    Dahut, W.L.3
  • 47
    • 0037299782 scopus 로고    scopus 로고
    • Side effects of androgen deprivation therapy: Monitoring and minimizing toxicity
    • Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2 Suppl 1):32-38.
    • (2003) Urology , vol.61 , Issue.2 SUPPL. 1 , pp. 32-38
    • Higano, C.S.1
  • 48
    • 11844252588 scopus 로고    scopus 로고
    • Risk of fracture after androgen deprivation for prostate cancer
    • Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352(2): 154-164.
    • (2005) N Engl J Med , vol.352 , Issue.2 , pp. 154-164
    • Shahinian, V.B.1    Kuo, Y.F.2    Freeman, J.L.3    Goodwin, J.S.4
  • 50
    • 30344468795 scopus 로고    scopus 로고
    • Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy
    • Bruder JM, Ma JZ, Basler J W, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology. 2006;67(1):152-155.
    • (2006) Urology , vol.67 , Issue.1 , pp. 152-155
    • Bruder, J.M.1    Ma, J.Z.2    Basler, J.W.3    Welch, M.D.4
  • 51
    • 33947222498 scopus 로고    scopus 로고
    • Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
    • Morote J, Morin J P, Orsola A, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69(3):500-504.
    • (2007) Urology , vol.69 , Issue.3 , pp. 500-504
    • Morote, J.1    Morin, J.P.2    Orsola, A.3
  • 52
    • 33645987269 scopus 로고    scopus 로고
    • Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
    • Morote J, Orsola A, Abascal JM, et al. Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression. J Urol. 2007;175(5):1679-1683.
    • (2007) J Urol , vol.175 , Issue.5 , pp. 1679-1683
    • Morote, J.1    Orsola, A.2    Abascal, J.M.3
  • 53
    • 0036296523 scopus 로고    scopus 로고
    • Clinical predictors of androgen-independent prostate cancer and survival in the prostate- specifc antigen era
    • Oefelein MG, Ricchiuti VS, Conrad P W, et al. Clinical predictors of androgen-independent prostate cancer and survival in the prostate- specifc antigen era. Urology. 2002;60(1):120-124.
    • (2002) Urology , vol.60 , Issue.1 , pp. 120-124
    • Oefelein, M.G.1    Ricchiuti, V.S.2    Conrad, P.W.3
  • 54
    • 67650924224 scopus 로고    scopus 로고
    • Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas
    • Mikami S, Katsube K, Oya M, et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009;218(4):530-539.
    • (2009) J Pathol , vol.218 , Issue.4 , pp. 530-539
    • Mikami, S.1    Katsube, K.2    Oya, M.3
  • 55
    • 33745821237 scopus 로고    scopus 로고
    • Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation
    • Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107(2):289-298.
    • (2006) Cancer , vol.107 , Issue.2 , pp. 289-298
    • Chen, G.1    Sircar, K.2    Aprikian, A.3    Potti, A.4    Goltzman, D.5    Rabbani, S.A.6
  • 56
    • 51249088776 scopus 로고    scopus 로고
    • A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer
    • Narita N, Yuasa T, Tsuchiya N, et al. A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer. BMC Cancer. 2008;8:224.
    • (2008) BMC Cancer , vol.8 , pp. 224
    • Narita, N.1    Yuasa, T.2    Tsuchiya, N.3
  • 57
    • 0036148405 scopus 로고    scopus 로고
    • Development of bisphosphonates
    • Fleisch H. Development of bisphosphonates. Breast Cancer Res. 2002; 4(1):30-34.
    • (2002) Breast Cancer Res , vol.4 , Issue.1 , pp. 30-34
    • Fleisch, H.1
  • 58
    • 77955457605 scopus 로고    scopus 로고
    • A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer
    • Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15(4): 382-389.
    • (2010) Int J Clin Oncol , vol.15 , Issue.4 , pp. 382-389
    • Zaghloul, M.S.1    Boutrus, R.2    El-Hossieny, H.3    Kader, Y.A.4    El-Attar, I.5    Nazmy, M.6
  • 59
    • 12244295754 scopus 로고    scopus 로고
    • A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo
    • Yuasa T, Nogawa M, Kimura S, et al. A third-generation bisphosphonate, minodronic acid (YM529), augments the interferon αβ-mediated inhibition of renal cell cancer cell growth both in vitro and in vivo. Clin Cancer Res. 2005;11(2 Pt 1):853-859.
    • (2005) Clin Cancer Res , vol.11 , Issue.2 PART 1 , pp. 853-859
    • Yuasa, T.1    Nogawa, M.2    Kimura, S.3
  • 60
    • 33751034291 scopus 로고    scopus 로고
    • A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo
    • Sato K, Yuasa T, Nogawa M, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer. 2006;95(10):1354-1361.
    • (2006) Br J Cancer , vol.95 , Issue.10 , pp. 1354-1361
    • Sato, K.1    Yuasa, T.2    Nogawa, M.3
  • 61
    • 82255162986 scopus 로고    scopus 로고
    • Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function
    • Maita S, Yuasa T, Tsuchiya N, et al. Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer. 2012;130(3):677-684.
    • (2012) Int J Cancer , vol.130 , Issue.3 , pp. 677-684
    • Maita, S.1    Yuasa, T.2    Tsuchiya, N.3
  • 62
    • 33645453481 scopus 로고    scopus 로고
    • Regulation of cancer cell migration and bone metastasis by RANKL
    • Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440(7084): 692-696.
    • (2006) Nature , vol.440 , Issue.7084 , pp. 692-696
    • Jones, D.H.1    Nakashima, T.2    Sanchez, O.H.3
  • 63
    • 78149284767 scopus 로고    scopus 로고
    • RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
    • Gonzalez-Suarez E, Jacob A P, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103-107.
    • (2010) Nature , vol.468 , Issue.7320 , pp. 103-107
    • Gonzalez-Suarez, E.1    Jacob, A.P.2    Jones, J.3
  • 64
    • 51049121618 scopus 로고    scopus 로고
    • RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis
    • Miller RE, Roudier M, Jones J, Armstrong A, Canon J, Dougall WC. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis. Mol Cancer Ther. 2008;7(7):2160-2169.
    • (2008) Mol Cancer Ther , vol.7 , Issue.7 , pp. 2160-2169
    • Miller, R.E.1    Roudier, M.2    Jones, J.3    Armstrong, A.4    Canon, J.5    Dougall, W.C.6
  • 65
    • 69049105440 scopus 로고    scopus 로고
    • Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen- deprivation therapy for prostate cancer
    • Smith MR, Egerdie B, Hernández Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen- deprivation therapy for prostate cancer. N Engl J Med. 2009;361(8): 745-755.
    • (2009) N Engl J Med , vol.361 , Issue.8 , pp. 745-755
    • Smith, M.R.1    Egerdie, B.2    Hernándeztoriz, N.3
  • 66
    • 79952360832 scopus 로고    scopus 로고
    • Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study
    • Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377(9768):813-822.
    • (2011) Lancet , vol.377 , Issue.9768 , pp. 813-822
    • Fizazi, K.1    Carducci, M.2    Smith, M.3
  • 67
    • 84855516339 scopus 로고    scopus 로고
    • Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: Results of a phase 3, randomised, placebo-controlled trial
    • Smith MR, Saad F, Coleman R, et al. Denosumab and bone-metastasis- free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012;379(9810): 39-46.
    • (2012) Lancet , vol.379 , Issue.9810 , pp. 39-46
    • Smith, M.R.1    Saad, F.2    Coleman, R.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.